CURRENT STATE OF LABORATORY DIAGNOSIS OF MATURE B-CELL LYMPHOID NEOPLASMS IN UKRAINE
DOI:
https://doi.org/10.32471/oncology.2663-7928.t-24-3-2022-g.10753Keywords:
atypical immunophenotype, chromosomal abnormalities, clinical outcome, gene mutations, hematological malignancies, minimal residual disease, prognosis, stage of diseaseAbstract
Mature B-cell lymphoid neoplasms constitute a heterogeneous group of diseases with variable clinical presentations ranging from indolent to very aggressive behavior. The revised (2016) WHO classification comprises more than 50 forms and clinicopathological variants of such neoplasms. The representative forms of mature B-cell lymphoid neoplasms (chronic lymphocytic leukemia/small lymphocytic lymphoma, hairy cell leukemia, lymphoplasmacytic lymphoma, marginal zone lymphoma, follicular lymphoma, mantle cell lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma and multiple myeloma) are characterized focusing on the current state of their diagnosing based on laboratory criteria according to the up-to-date requirements. The diagnosis is based on the detection of typical morphological features and histological and immunohistochemical analysis of trephine biopsies combined with immunophenotyping of the neoplastic cells by flow cytometry. The landscape of various types of chromosomal aberrations and molecular genetic abnormalities in mature B-cell neoplasms and their application in disease diagnosis especially in the cases with atypical laboratory findings are also discussed.
References
Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127 (20): 2375–90. doi: 10.1182/blood-2016-01-643569.
Zelenetz AD, Gordon LI, Ambramson JS, et al. B-cell lymphomas. NCCN Evidence Blocks. Version 5.2022. 2022 https://www.nccn.org/professionals/physician_gls/pdf/b-cell_blocks.pdf
Wierda WG, Brown J, Ambramson JS, et al. Chronic lymphocytic leukemia/Small lymphocytic lymphoma. NCCN Evidence Blocks. Version 1.2023. 2022. https://www.nccn.org/professionals/physician_gls/pdf/cll_blocks.pdf.
Kumar SK, Callander NS, Adekola K, et al. Multiple myeloma. NCCN Evidence Blocks. Version 5.2022. 2022 https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf
Diagnosis and treatment of chronic lymphoid leukemia. Adapted evidence-based clinical guidelines (updated). State Expert Center of the Ministry of Health of Ukraine 2016, 84 p (in Ukrainian) https://www.dec.gov.ua/wp-content/uploads/2019/11/2016_439_akn_hll.pdf.
Diagnosis and treatment of lymphoma in adults. Adapted evidence-based clinical guidelines (updated). State Expert Center of the Ministry of Health of Ukraine 2013, 395 p (in Ukrainian) https://www.dec.gov.ua/wp-content/uploads/2019/11/2013_866kn_limfomy.pdf.
Diagnosis and treatment of multiple myeloma. Adapted evidence-based clinical guidelines (updated). State Expert Center of the Ministry of Health of Ukraine 2015, 170 p (in Ukrainian) https://www.dec.gov.ua/wp-content/uploads/2019/11/2015_710_akn_mm.pdf.
Philchenkov AA, Sklyarenko LM. Chronic lymphocytic leukemia: problems of diagnosis and therapy. Oncology 2017; 19 (4): 235–46 (in Russian).
Cerhan JR, Slager SL. Familial predisposition and genetic risk factors for lymphoma. Blood 2015; 126 (20): 2265–73. doi: 10.1182/blood-2015-04-537498.
Gluzman DF, Sklyarenko LM, Koval SV, et al. Cytology and immunocytochemistry of B-cell non-Hodgkin’s lymphomas. Kiev: DIA, 2015. 55 p (in Russian).
Tran J, Gaulin C, Tallman MS. Advances in the treatment of hairy cell leukemia variant. Curr Treat Options Oncol 2022; 23 (1): 99–116. doi: 10.1007/s11864-021-00927-z.
Juárez-Salcedo LM, Castillo JJ. Lymphoplasmacytic lymphoma and marginal zone lymphoma. Hematol Oncol Clin North Am 2019; 33 (4): 639–656. doi: 10.1016/j.hoc.2019.03.004.
Bertoni F, Rossi D, Raderer M, Zucca E. Marginal zone lymphomas. Cancer J 2020; 26 (4): 336–47. doi: 10.1097/PPO.0000000000000463.
Alderuccio JP, Kahl BS. Current treatments in marginal zone lymphoma. Oncology (Williston Park). 2022; 36 (4): 206–15. doi: 10.46883/2022.25920956.
Cartron G, Trotman J. Time for an individualized approach to first-line management of follicular lymphoma. Haematologica 2022; 107 (1): 7–18. doi: 10.3324/haematol.2021.278766.
Khanlari M, Chapman JR. Follicular lymphoma: updates for pathologists. J Pathol Transl Med 2022; 56 (1): 1–15. doi: 10.4132/jptm.2021.09.29.
Varanese M, Lauro A, Lattina I, et al. Duodenal follicular lymphoma: Track or treat? Dig Dis Sci 2022; 67 (5): 1733–8. doi: 10.1007/s10620-022-07498-5.
Takiar R, Phillips T. Non-chemotherapy options for newly diagnosed mantle cell lymphoma. Curr Treat Options Oncol 2021; 22 (11): 98. doi: 10.1007/s11864-021-00900-w.
Crombie J, LaCasce A. The treatment of Burkitt lymphoma in adults. Blood 2021; 137 (6):743–50. doi: 10.1182/blood.2019004099.
Philchenkov AA. Bone marrow adipocytes and multiple myeloma. Oncohematology 2019; 14 (1): 60–75 (in Russian). doi: 10.17650/1818-8346-2019-14-1-60-75.
Bustoros M, Anand S, Sklavenitis-Pistofidis R, et al. Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes. Nat Commun 2022; 13 (1): 3449. doi: 10.1038/s41467-022-30694-w.
Rawstron AC, Kreuzer KA, Soosapilla A, et al. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. Cytometry B Clin Cytom 2018; 94 (1): 121–8. doi: 10.1002/cyto.b.21595.
Eichhorst B, Robak T, Montserrat E, et al.; ESMO Guidelines Committee. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2021; 32 (1): 23–33. doi: 10.1016/j.annonc.2020.09.019.
Gattei V, Bulian P, Del Principe MI, et al. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood 2008; 111 (2): 865–73. doi: 10.1182/blood-2007-05-092486.
Sklyarenko LМ, Polishchuk АS, Ivanivska TS, et al. Immunophenotypical characteristics of villous lymphocytes in B-cell lymphoprolifative diseases. Oncology 2019; 21 (3): 208–12 (in Ukrainian).
Cabeçadas J, Nava VE, Ascensao JL, Gomes da Silva M. How to diagnose and treat CD5-positive lymphomas involving the spleen. Curr Oncol 2021; 28 (6): 4611–33. doi: 10.3390/curroncol28060390.
Sklyarenko LМ, Polishchuk АS, Ivanivska TS, et al. Immunophenotypical features of blastoid variant of mantle cell lymphoma. Oncology 2019; 21 (2): 113–6 (in Ukrainian).
Gluzman DF, Sklyarenko LM, Ivanovskaya TS, et al. Immunocytochemical studying of blood and bone marrow cells in diagnosing B-cell lineage non-Hodgkin’s lymphomas. Oncology 2015; 17 (1): 25–30 (in Russian).
Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103 (1): 275–82. doi: 10.1182/blood-2003-05-1545.
Meyer PN, Fu K, Greiner TC, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 2011; 29 (2): 200–7. doi: 10.1200/JCO.2010.30.0368.
International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol 2016; 17 (6): 779–90. doi: 10.1016/S1470-2045(16)30029-8.
Andreieva SV, Korets KV, Skorohod IM, et.al. Cytogenetic and molecular cytogenetic investogations in relapse of B cell chronic lymphocytic leukemia. Cytol Genet 2017; 51 (3): 155–61. doi: 10.3103/S0095452717030021.
Andreieva SV, Korets KV, Ruzhinska OE, et al. Comparison of chromosomal rearrangements in bone marrow cells and blast transformed B-cells in relapse of B-cell chronic lymphovytic leukemia/small lymphocytic lymphoma. Exp Oncol 2017; 39 (2): 141–4. PMID: 29483496.
Roider T, Falini B, Dietrich S. Recent advances in understanding and managing hairy cell leukemia. F1000Res 2018; 7: F1000 Faculty Rev-509. doi: 10.12688/f1000research.13265.1.
Ritterhouse LL, Barletta JA. BRAF V600E mutation-specific antibody: A review. Semin Diagn Pathol 2015; 32 (5): 400–8. doi: 10.1053/j.semdp.2015.02.010.
Zhang W, Ao Q, Guan Y, et al. A novel diagnostic approach for the classification of small B-cell lymphoid neoplasms based on the NanoString platform. Mod Pathol 2022; 35 (5): 632–9. doi: 10.1038/s41379-021-00954-z.
Devin J, Kassambara A, Bruyer A, et al. Phenotypic characterization of diffuse large B-cell lymphoma cells and prognostic impact. J Clin Med 2019; 8 (7): 1074. doi: 10.3390/jcm8071074.
